MHE Staff

In a discussion with Managed Healthcare Executive, Robert Sidbury, M.D., M.P.H, FAAD, professor of pediatrics at the Seattle Children's Hospital talks about what it takes to run a dermatology practice and how to implement value-based care initiatives.

At the American Academy of Dermatology meeting in San Diego, Raj J. Chovatiya, M.D., Ph.D, discussed the evolution of studies on Jak inhibitors post-approval.

The results of this week’s poll about health insurance coverage of GLP-1s for weight loss.

In a discussion with Managed Healthcare Executive, Jonathan I. Silverberg, M.D., Ph.D., M.P.H., an Associate Professor of Dermatology at The George Washington University School of Medicine and Health Sciences, discussed the concept of "atopic march."

John Barbieri, assistant professor at Harvard Medical School, is looking forward to the upcoming 2024 American Academy of Dermatology meeting, which runs from March 8-12 in San Diego. Barbieri is particularly showing interest in late-breaking abstracts and trial data and hoping to see cutting-edge information from pivotal clinical trials.

The research grant will examine barriers to access to continuous glucose monitoring, which is widely seen as having advantages over keeping tabs of blood sugar levels with finger pricks,

Please pick the statement that most closely resembles your view of health insurance coverage of GLP-1s for weight loss.

Both Wyost and Jubbonti are interchangeable for the reference products and are approved for all of the same indications in osteoporosis and bone cancer.

The results of this week’s poll about the recent Change Healthcare Cyberattack.

Christopher Starr, M.D., of Weill Cornell Medical College in New York discusses of the challenges of making a diagnosis and a new treatment.

The Prescription Drug User Fee Act action date is Aug. 28, 2024.

Share your view about the Change Healthcare cyberattack.

The results of this week’s poll about Medicaid work requirements.

Linvoseltamab is bispecific antibody designed to treat relapsed/refractory multiple myeloma. The FDA’s target action date is Aug. 22, 2024

Amtagvi was approved to treat patients with advanced melanoma. It is a one-time cell therapy that will be administered at authorized treatment centers and have a wholesale acquisition cost of $515,000.

Do you favor Medicaid work requirements?

The results of this week’s poll about Super Bowl LVIII commercials.

Which of these was your favorite Super Bowl commercial?

A recent survey by the American Academy of Dermatology showed that only 13% of Americans plan to use sun protection when going for walks or hikes in cold weather.

The drugmaker is spending $15 million over a three-year period to address cancer care disparities in breast and prostate cancer.

The results of this week’s poll about site-neutral payment extensions.

Should site-neutral payment rules and policies be extended to commercial payers, payment for physician-administered drugs, and services delivered in on-campus hospital outpatient departments?

Leaders at City of Hope, a cancer research and care center in Los Angeles, forecast that in 2024 more people will benefit from cancer breakthroughs.

Once the transaction is complete in the first quarter of 2025, Evernorth Health Services will continue to provide pharmacy benefit services to the Medicare businesses.

CMS said in a news release today that 13.7 million beneficiaries are in accountable care organizations (ACOs) and that a total of 480 ACOs are participating in the Medicare Shared Savings Program (MSSP).

After anticipation of integrating two health systems for the last two years, Essentia Health and Marshfield Clinic Health System (MCHS) recently announced their merger will no longer be in effect.

The Philadelphia-based insurer has selected four winners.

Adam Fein, founder of Drug Channels, said the acquisition will allow the company to upgrade its technology, grow the company and provide live and in-person events.

We caught up recently with William Shrank, M.D., a longtime member of the Managed Healthcare Executive editorial advisory board. Shrank has held several executive positions with health insurers, most recently Humana. He is now a venture partner with Andreessen Horowitz, a venture capital firm in Menlo Park, California.